- Home
- HNI vs SCLXW Comparison
HNI vs SCLXW Comparison
Compare HNI & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNI
- SCLXW
- Stock Information
- Founded
- HNI 1944
- SCLXW N/A
- Country
- HNI United States
- SCLXW United States
- Employees
- HNI N/A
- SCLXW 117
- Industry
- HNI Office Equipment/Supplies/Services
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- HNI Consumer Discretionary
- SCLXW Health Care
- Exchange
- HNI Nasdaq
- SCLXW Nasdaq
- Market Cap
- HNI N/A
- SCLXW N/A
- IPO Year
- HNI N/A
- SCLXW N/A
- Fundamental
- Price
- HNI $45.43
- SCLXW $0.10
- Analyst Decision
- HNI Strong Buy
- SCLXW
- Analyst Count
- HNI 1
- SCLXW 0
- Target Price
- HNI $63.00
- SCLXW N/A
- AVG Volume (30 Days)
- HNI 457.8K
- SCLXW 4.0K
- Earning Date
- HNI 04-28-2025
- SCLXW 03-07-2025
- Dividend Yield
- HNI 2.94%
- SCLXW N/A
- EPS Growth
- HNI 164.22
- SCLXW N/A
- EPS
- HNI 2.88
- SCLXW N/A
- Revenue
- HNI $2,526,400,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- HNI $3.51
- SCLXW N/A
- Revenue Next Year
- HNI $3.75
- SCLXW N/A
- P/E Ratio
- HNI $15.55
- SCLXW N/A
- Revenue Growth
- HNI 3.80
- SCLXW 22.02
- 52 Week Low
- HNI $40.94
- SCLXW $0.18
- 52 Week High
- HNI $58.42
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- HNI 51.80
- SCLXW N/A
- Support Level
- HNI $43.72
- SCLXW N/A
- Resistance Level
- HNI $45.71
- SCLXW N/A
- Average True Range (ATR)
- HNI 0.97
- SCLXW 0.00
- MACD
- HNI 0.33
- SCLXW 0.00
- Stochastic Oscillator
- HNI 90.79
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.